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1 |  INTRODUCTION
Microvillous inclusion disease (MVID) is a rare severe con-
genital diarrheal disorder due to the dysfunction of myosin 
Vb protein encoded by MYO5B gene. About 40 different 
mutations were described so far in patients with sporadic 
MVID. We describe two patients of Italian origin, bearing 
novel MYO5B mutations. The first one was homozygous for 
the novel mutation c.505A>G in exon 5 of MYO5B gene, and 
the second was compound heterozygous for the mutations 
c.1367A>G and c.2700delG (novel). Several bioinformatic 
tools were concordant on the pathogenicity of such mutations 
confirming that molecular analysis is a rapid and effective 
approach to specifically diagnose MVID among the myriad 
of conditions that cause severe diarrhea in early life.
Microvillous inclusion disease (MVID, OMIM 251850) 
is a rare congenital diarrheal disorder (CDD) inherited as 
an autosomal recessive trait.1,2 It typically presents with se-
vere chronic diarrhea in the few days after birth and rapidly 
causes dehydration and metabolic acidosis. No additional 
onset symptoms distinguishable from other CDDs are usu-
ally present in MVID patients born via normal delivery 
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Key Clinical Message
Microvillous inclusion disease (MVID) typically appears with severe chronic 
 diarrhea in the few days after birth and rapidly causes dehydration and metabolic 
acidosis. In this context, presenting two novel cases, we underline the crucial 
importance of mutation analysis for the diagnosis of this disease that may be 
 easily misdiagnosed.
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after an uneventful pregnancy with no polyhydramnios.3 A 
timely diagnosis is mandatory, and total parenteral nutrition 
is necessary for most MVID patients, even if it may cause 
cholestasis and liver failure. The outcome of the disease is 
usually fatal within 2‐3 years4 due to severe dehydration 
and electrolyte unbalance, even if intestinal transplantation 
may improve the outcome.5 MVID has a better prognosis 
when the onset occurs within the first 3‐4 months of life 
and there is less severe diarrhea with some residual intes-
tinal functionality, which reduces the need for parenteral 
nutrition.2 Forms of MVID with unusual onset have been 
also reported.6
Microvillous inclusion disease is classified within the sub-
group of CDDs caused by defects of enterocyte polarization 
and differentiation7 that are due to the dysfunction of myosin 
Vb protein, an actin filament‐based motor protein that is in-
volved in endosomal recycling and in cytoskeleton cell polar-
ity determination. Small intestine biopsy shows the atrophy 
of villi with microvillus inclusion, crypt hyperplasia, and a 
mild (if any) inflammatory infiltration.8‒10 In fact, the main 
characteristic of MVID is the loss of the apical brush border 
and the formation of intracellular microvillus inclusions. The 
microvillus inclusions are usually observed in approximately 
10% of enterocytes at the villus tips, whereas normal brush 
borders are often present on the enterocytes in the proximal 
part of the villus.9,10 Focal or delayed alterations may be pres-
ent in atypical MVID.6
Most patients with early‐onset MVID display inactivating 
mutations in the MYO5B gene11 encoding myosin Vb protein. 
MYO5B works as a dynamic tether for specific RAB‐small 
GTPases (RAB8A, RAB10, and RAB11) maintaining these 
proteins at their appropriate subapical membrane localiza-
tion. This interaction is crucial for a normal epithelial cell 
polarity, apical trafficking, and microvilli growth. Alterations 
in this interaction, deriving from mutations in MYO5B, lead 
to a mucosa with decreased absorptive pathways and a leaky 
epithelium at the villus tips, which causes alterations in both 
intercellular tight junctions and the ion transport pathways 
necessary for adaptation through trans‐cellular pumps and 
channels.12
Once MYO5B is identified as the disease gene for MVID, 
molecular analysis strongly contributes to the unequivocal 
diagnosis of MVID11‒13 and even prenatal diagnosis.14,15 
A founder mutation was identified among Navajos16 while 
about 60 different mutations were described so far in patients 
from other ethnic groups indicating the strong genetic het-
erogeneity of the disease. These findings were reviewed in 
the excellent papers by van der Velde17 and Dhekne.18 More 
recently, the Syntaxin 3 gene was reported as responsible for 
an MVID variant.19
In the present paper, we describe two cases of MVID 
bearing novel MYO5B mutations and revise the pathogenic 
role of MYO5B mutations described in MVID patients so far.
2 |  METHODS
2.1 | Molecular analysis of the MYO5B gene
DNA was extracted from an EDTA blood sample with the 
Nucleon BACC2 kit (GE Healthcare Europe GmbH, Milan, 
Italy). Then, the DNA was amplified by PCR for all 40 exons 
of the MYO5B gene using primers and conditions available 
on request. A DHPLC procedure was used to exclude the 
presence of the novel MYO5B mutations in 100 alleles from 
50 healthy subjects.
2.2 | Prediction of disease‐associated variation
Protein sequence with the different amino acid variations was 
submitted to the Meta‐SNP browser (https://snps.biofold.org/
meta-snp/pages/methods.html), which integrates four exist-
ing methods for disease association prediction: PANTHER, 
PhD‐SNP, SIFT, and SNAP.20
2.3 | Subjects
Case #1. A male infant of Caucasian origin with a history 
of diarrhea since the first week of life, hypernatremic de-
hydration, hyperchloremic metabolic acidosis, and failure 
to thrive as observed in a tertiary center for pediatric gas-
troenterology. He was born at 36 weeks of gestational age 
by cesarean delivery, from nonconsanguineous and healthy 
parents. Pregnancy was complicated by premature birth 
threats. Family history was negative for early‐onset diar-
rhea. Birth weight was 2820 g. The patient required hos-
pitalization from the first days of life because of the onset 
of severe watery diarrhea and dehydration associated with 
metabolic acidosis, hypernatremia, hyperchloremia, and 
hyperammonemia. At admission, he was 2 months old and 
he appeared sick, pale, and sleepy, with conserved con-
sciousness. Body temperature, blood pressure, and cardio‐
respiratory function were within normal range for his age. 
There was a normal abdominal examination. Auxologic pa-
rameters were weight 2940 g, length 50 cm, and CC 36 cm. 
He assumed total parenteral nutrition since the first days 
of hospitalization. In order to investigate the etiology of 
chronic diarrhea, an extensive diagnostic workup was per-
formed, including inflammatory biomarkers, stool micro-
biology, sweat test, food allergy screening tests, metabolic 
screening tests, and fecal calprotectin.21‒23 All these tests 
resulted negative. Mean electrolytes values and fecal os-
molarity were as follows: Na+ 62 mEq/L; K+ 39 mEq/L; 
Cl‐ 69 mEq/L; Osm 262 mOsm/kg; anion gap 60. Duodenal 
histology showed intestinal villous atrophy (cod.T3a of 
Marsh classification modified by Oberhuber). Electron 
microscopy analysis of the duodenal mucosa described a 
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T A B L E  1  MYO5B gene mutations found in patients with microvillous inclusion disease
Ancestry G. Mutations E/I Protein Effect Ref.
Italian M c.505A>G (Hom) 5 p.Lys169Glu Missense This work
Italian M c.1367A>G 11 p.Asn456Ser Missense 13
c.2700delG 21 p.Arg900SerfsX4 Frameshift This work
Algerian Arabic F c.866C>A 8 p.Ser289X Nonsense 11
c.4840C>T 36 p.Qln1614X Nonsense
Turkish M c.502G>A (Hom) 5 p.Gly168Arg Missense 11
Algerian Arabic M c.4667_4668TT>GC (Hom) 35 p.Leu1556Arg Missense 11
Italian F c.1202G>A (Hom) 10 p.Arg401His Missense 11
French F c.1303G>A 10 p.Gly435Arg Missense 11
Unknown
French M c.42G>A 2 p.Trp14X Nonsense 11
c.428C>A 4 p.Ala143Glu Missense
Kosovo M c.28‐2A>G Splicing 11
c.1202G>A 10 p.Arg401His Missense
Portuguese F c.1110_1113delTCAG 10 p.Ser370ArgfsX27 Frameshift 11
c.4755_4576dupT 36 p.Asp1586X Stop codon
Italian F c.2003‐2A>G (Hom) I 16 Splicing 11
French M c.557C>A 5 p.Ser186X Nonsense 11
c.1A>G 1 p.Met1?
Turkish M c.947‐1G>A (Hom) I 8 Splicing 11
Navajo (9 cases) c.1979C>T (Hom) 16 p.Pro660Leu Missense 16
Hispanic M c.946G>A (Hom) 8 p.Gly316Arg Missense 13
Hispanic F c.2330delG (Hom) 19 p.Gly777AspfsX6 Frameshift 13
Caucasian F c.2245C>T 19 p.Arg749X Nonsense 13
Unknown
Polish F c.28?_1545+?del 2‐12
c.1367A>G 11 p.Asn456Ser Missense
Moroccan M c.4366C>T (Hom) 33 p.Gln1456X Nonsense 13
Dutch M c.4460‐1G>C I 33 Splicing 13
c.1540T>C 12 p.Cys514Arg Missense
French F c.2671C>T 21 p.Q891X Nonsense 12
Unknown
Turkish M c.656G>A (Hom) 6 p.R219H Missense 12
Irish M c.3046C>T 23 p.R1016X Nonsense 12
Unknown
Turkish M c.5392C>T (Hom) 39 p.R1795X Nonsense 12
Turkish M c.1966C>T (Hom) 16 p.R656C Missense 12
Turkish M c.1125G>A (Hom) 10 p.W375X Nonsense 12
Turkish M c.323T>G (Hom) 4 p.V108G Missense 12
Turkish M c.1323‐2A>G (Hom) I 10 Splicing 12
Turkish F c.1362insAGTTCTGTA (Hom) 11 p.Cys454insKFC Insertion 12
Taiwan M c.445C>T 4 p.Gln149X Nonsense 14
c.1021C>T 9 p.Gln341X Nonsense
Caucasian M c.1087C>T 10 p.Arg363X Nonsense 17
Unknown
(Continues)
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submicroscopic pattern characteristic of MVID, charac-
terized by intestinal mucosa with partial villous atrophy, 
enterocyte‐depleted microvillous (which were not well ori-
ented and absent in some sections), several intracytoplas-
matic microvillar inclusions, and dense granules.
The clinical history was characterized by watery diarrhea; 
metabolic acidosis; failure to thrive; relapsing sepsis; bilateral 
congenital cataract; retinitis pigmentosa; hypopigmentation of 
skin and hair; recurrent urinary tract infections; delayed psycho-
motor development. The patient was dependent on total paren-
teral nutrition. The patient died at the age of 23 months during 
a severe sepsis with a clinical picture of macrophage activation 
syndrome (MAS) unsuccessfully treated with cyclosporine and 
steroids.
Case #2. A male infant of Caucasian origin with a history 
of diarrhea since the first 10 days of life, metabolic acidosis, 
and failure to thrive as observed in a tertiary center for pediatric 
gastroenterology. He was born at 37 weeks of gestational age 
by cesarean delivery, from nonconsanguineous and healthy par-
ents. The pregnancy was complicated by mild polyhydramnios. 
Birth weight was 3280 g. His older sister died at one month of 
age because of severe dehydration, metabolic acidosis, hyper-
ammonemia, and bowel perforation. From the first days of life, 
he was hospitalized for the onset of severe diarrhea and dehydra-
tion associated with metabolic acidosis, hypernatremia, hyper-
chloremia, and hyperammonemia. At admission, he was 37 days 
old and he appeared sick, pale and with abdominal distension. 
Auxologic parameters were: weight 3090 g, length 51 cm, CC 
35.8 cm. He assumed total parenteral nutrition from the first days 
of hospitalization. In order to investigate the etiology of chronic 
diarrhea, the same extensive diagnostic workup previously de-
scribed was performed,21‒23 but all tests resulted negative. Mean 
electrolytes values and fecal osmolarity were as follows: Na+ 
94 mEq/L; K+ 16 mEq/L; Cl‐ 78 mEq/L; Osm 268 mOsm/kg; 
anion gap 48. Duodenal histology showed villous atrophy (cod.
T3a of Marsh classification modified by Oberhuber). Electron 
microscopy revealed MVID features with villous atrophy, with 
microvillus inclusion bodies within the cytoplasm of enterocytes 
with rarefied microvilli and secretory granules.
The clinical history was characterized by metabolic acido-
sis requiring frequent daily NaHCO3 oral intake; ammonium 
urate stone urinary excretion; neutrophilic leukocytosis with-
out overt signs of inflammation and/or infection; presence of 
PAS‐positive vacuoles at muscle biopsy; failure to thrive; thin 
and inelastic skin with prominent cheekbones; and thin lips. The 
patient did not tolerate nutritional support with minimal enteral 
feeding and was dependent on total parenteral nutrition.
The patient died at the age of 7 months following a drug‐
resistant epilepsy with respiratory distress.
All the participants (guardians in the case of minors) pro-
vided written informed consent to anonymously use a DNA 
sample and clinical data for research purposes.
3 |  RESULTS
Case #1: Molecular analysis revealed the homozygous muta-
tion c.505A>G in exon 5 of the MYO5B gene. To exclude the 
presence of a heterozygous deletion, we analyzed the parents, 
which resulted in both being heterozygous for the c.505A>G 
mutation. The mutation was novel not previously described in 
MVID patients. It is a missense mutation that causes the change 
of the lysine (Lys, K) with glutamic acid (Glu, E) at the codon 
169 (p.Lys169Glu) (see Table 1).
Case #2: Molecular analysis revealed the heterozygous 
mutations c.1367A>G and c.2700delG in trans (Table 1), 
as confirmed by the analysis of the parents. The novel muta-
tion c.2700delG changes the arginine (Arg, R) with serine 
(Ser, S) at codon 900 causing a frameshift from the codon 900 
(p.Arg900Serfs*4). The missense mutation c.1367A>G causes 
the change in the asparagine (Asn, N) with serine (Ser, S) at 
the codon 456 (p.Asn456Ser). This has already been found in a 
patient with MVID.13
4 |  DISCUSSION
Severe chronic diarrhea in the newborn is a serious challenge 
because it may be a potentially life‐threatening condition and 
because a differential diagnosis is required among a myriad of 
different conditions.7 This is particularly true for MVID con-
sidering that: (a) a rapid and specific diagnosis is mandatory 
in order to immediately start the parenteral nutrition, followed, 
when possible, by intestinal transplantation3; (b) the diagno-
sis of MVID may be complex due to the heterogeneity of the 
clinical phenotype,3,4 and histologic diagnosis is invasive and 
Ancestry G. Mutations E/I Protein Effect Ref.
Turkish M c.3163_3165dupCTC 24 p.Leu1055dup Duplication 17
Unknown
Dutch F c.5616‐2A>G 40 Splicing 17
c.1591C>T 13 p.Arg531Trp Missense
c.1856C>T 15 p.Pro619leu Missense
E/I, exon/intron, F, female, G, Gender, (Hom), patient homozygous for the indicated mutation, M, male.
TABLE 2 (Continued)
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sometimes challenging17; and (c) cases of MVID with atypical 
presentation were described.6 In this scenario, molecular genet-
ics may significantly contribute to rapid diagnosis reducing the 
need for invasive procedures. However, sequencing analysis 
may identify novel mutation for which several approaches to as-
sess their causative role are required.24
In fact, our patient #1 was homozygous for the c.505A>G 
(p.Lys169Glu) novel mutation, while patient #2 was compound 
heterozygous for the c.2700delG (p.Arg900Serfs*4), a novel 
frameshift mutation (thus with a clear pathogenic role), and the 
c.1367A>G (p.Asn456Ser), already found in a Polish MVID 
patient who was compound heterozygous for the p.Asn456Ser 
mutation.13 Thus, we followed several criteria to define the 
pathogenic effect of either the p.Lys169Glu or the p.Asn456Ser 
missense mutations: (a) No other mutations were found in the 
whole coding regions of the MYO5B gene in the patients (includ-
ing exon‐intron boundaries); (b) p.Lys169Glu mutation changed 
a neutral with an acidic amino acid within the ATP‐binding regu-
latory domain of the protein11; (c) both mutations were absent in 
100 alleles from 50 healthy subjects from the same ethnic group 
of the patients (southern Italy) tested by DHPLC; moreover, the 
novel mutations were not reported in the Exome Variant Server 
(https://evs.gs.washington.edu/EVS/) (August 2018) and in the 
1000 genome browser (https://phase3browser.1000genomes.
org/index.html). Both browsers consider more than 8000 sub-
jects; and (d) several tools20 predicted a high damaging proba-
bility of both mutations (Table S1).
The described mutations of our two patients should be added 
to cases17 previously described in patients affected by MVID 
(Table 1), and such list warrants some comments. MVID has 
a higher frequency among Navajos, where a single mutation 
(ie, the c.1979C>T) was found in the nine cases described so 
far,13,14 due to the high incidence of consanguineous marriages. 
However, a strong genetic heterogeneity was found in sporadic 
cases reported so far (Table 1). In fact, considering the MVID 
patients homozygous for a mutation (mostly born to consan-
guineous parents) and the patients that were compound hetero-
zygous, causative mutations spread in all coding regions of the 
gene. Once excluded, of the two affected siblings described by 
Szperl et al, who were homozygous for the same mutation, only 
one mutation was found in each MVID patient: The c.1202G>A 
was found homozygous in a MVID patient of Italian origin 
and compound heterozygous in a patient from Kosovo. The 
c.1367A>G was found compound heterozygous in two patients 
(one Polish and the other Italian described in the present study). 
All the other mutations were found in single MVID patients. 
Finally, 62 different mutations (including the c.1979C>T that is 
peculiar to Navajos) were found in the MVID patients studied so 
far.18 Several of these mutations have a clear pathogenic effect 
(ie, nonsense, splicing, or frameshift), while 24 were missense. 
We revised 15 of them by using several bioinformatic tools 20 
and predicted the pathogenicity (Table S1) in all cases with the 
exception of the c.1856C>T mutation, which was found in a 
Dutch patient with MVID that had two other pathogenic mu-
tations (Table 1). Of Course, functional studies are needed to 
prove their putative pathogenicity.
Noteworthy, among the 33 sporadic cases tested by gene 
sequencing, two causative mutations were found in 27 cases 
(81.8%) while only a single mutation was found in six cases, 
showing a mutation detection rate of 90.9%, which is similar 
to other sequencing analysis (ie, hemophilia A and cystic fi-
brosis).20,25 It is possible that mutations in noncoding regions 
of the gene, like the promoter or 3’UTR (that are not currently 
analyzed), would be present in patients bearing undetected mu-
tations in the coding regions of the MYO5B gene, as shown for 
other genetic diseases.26,27 It is also possible that other genes 
have a role.19 Finally, in contrast to other congenital diarrhea, in 
which molecular analysis may help to predict the outcome of the 
disease or to guide the therapy,28 in MVID there is not a clear 
genotype‐phenotype correlation because the prognosis of the 
disease is strictly dependent on early and effective management, 
including intestinal transplantation.2,3,17
To conclude, our data confirm the relevance of molecular 
analysis to rapidly diagnose MVID and underline the importance 
to update the database with novel mutations found in patients to 
help other laboratories that perform molecular analysis.17 The 
absence of the mutation in normal subjects tested with scanning 
procedures like DHPLC,29 and the use of prediction tools may 
contribute to defining the role of novel mutations (mainly mis-
sense) for which a pathogenic role may be difficult to establish.
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